Tolerability Profiles of Leukotriene Receptor Antagonists and Long-Acting β₂-Adrenoceptor Agonists in Combination with Inhaled Corticosteroids for Treatment of Asthma: A Review

References

• Salvi S S, Krishna M T, Sampson A P, Holgate S T. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119: 1533–1546
   PubMed Web of Science ®Google Scholar
• Lazaar A L, Panettieri R A, Jr. Airway smooth muscle: a modulator of airway remodeling in asthma. J Allergy Clin Immunol 2005; 116: 488–495
   PubMed Web of Science ®Google Scholar
• Bousquet J, Jeffery P K, Busse W W, Johnson M, Vignola A M. Asthma: from bronchocostriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720–1745
   PubMed Web of Science ®Google Scholar
• Vignola A M. Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting β2-agonists on asthma pathophysiology: a review of the evidence. Drugs 2003; 63(suppl 2)35–51
   PubMedGoogle Scholar
• Canham E M, Martin R J. Current treatment options for asthma in adults. Panminerva Med 2005; 47: 109–122
   PubMedGoogle Scholar
• Prasad N R, Bahekar R H, Rao A R. Recent perspectives in the design of antiasthmatic agents. Pharmazie 2000; 55: 475–482
   PubMedGoogle Scholar
• Guidelines for the diagnosis and management of asthma [publication 97-4051]. United States Department of Health and Human Services, Public Health Service, NIH, National Heart, Lung and Blood Institute, Bethesda, MD 1997, National Asthma Education and Prevention Program. Expert Panel Report 2.
   Google Scholar
• Doull I J, Williams A A, Freezer N J, Holgate S T. Descriptive study of cough, wheeze and school absence in childhood. Thorax 1996; 51: 630–631
   PubMedGoogle Scholar
• Janson C, Chinn S, Jarvis D, Burney P. on behalf of the European Community Respiratory Health Survey. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J 1997; 10: 1795–1802
   PubMed Web of Science ®Google Scholar
• Walsh L J, Wong C A, Cooper S, Guhan A R, Pringle M, Tattersfield A E. Morbidity to asthma in relation to regular treatment: a community based study. Thorax 1999; 54: 296–300
   PubMed Web of Science ®Google Scholar
• Suissa S, Erns P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336
   PubMed Web of Science ®Google Scholar
• Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999; 83: 153–179
   PubMed Web of Science ®Google Scholar
• Jackson L D, Polygenis D, McIvor R A, Worthington I. Comparative efficacy and safety of inhaled corticosteroids in asthma. Can J Clin Pharmacol 1999; 6: 26–37
   PubMedGoogle Scholar
• Cochrane M G, Bala M V, Downs K E, Mauskopf J, Ben-Joseph R H. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–550
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Albano M, Canonica G W, Bachert C, Van Cauwenberge P, Davies R J, Durham S R, Kontou-Fili K, Horak F, Malling H J. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16–33
   PubMed Web of Science ®Google Scholar
• Harding S M. The human pharmacology of fluticasone propionate. Respir Med 1990; 84: 25–29
   PubMed Web of Science ®Google Scholar
• Richards D H, Daley-Yates P T. Choice of inhaled and intranasal steroids when used in combination for asthma and rhinitis in children. 19th Congress of the European Academy of Allergology and Clinical Immunology, LisbonPortugal, 2000, Abstract 185
   Google Scholar
• Brutsche M H, Brutsche I C, Munawar M, Langley S J, Masterson C M, Daley-Yates P T, Brown R, Custovic A, Woodcock A. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556–561
   PubMed Web of Science ®Google Scholar
• Bisgaard L, Allen D, Milanowski J, Kalev I, Willets L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone proprionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113: e89–e94
   Google Scholar
• Todd G RG, Acerini C L, Ross-Russell R, Zahra S, Warner J T, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457–461
   PubMed Web of Science ®Google Scholar
• Todd G RG. Adrenal crisis due to inhaled steroids is underestimated. Arch Dis Child 2003; 88: 554–555
   PubMedGoogle Scholar
• World Health Organization. Safety Issues. Fluticasone and adrenal crisis. WHO Drug Information 2003; 17: 92
   Google Scholar
• Salvatoni A, Piantanida E, Nosetti L, Nespoli L. Inhaled corticosteroids in childhood asthma: long-term effects on growth and adrenocortical function. Pediatr Drugs 2003; 5: 351–361
   PubMedGoogle Scholar
• Skooner D P. Balancing safety and efficacy in pediatric asthma management. Pediatrics 2002; 109: 381–392
   PubMedGoogle Scholar
• Belvisi M G, Brown T J, Wicks S, Foster M L. New glucocorticosteroids with an improved therapeutic ratio. Pulm Phramacol Ther 2001; 14: 221–227
   PubMed Web of Science ®Google Scholar
• Allen D B, Julius J R, Breen T J, Attie K M. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998; 83: 2824–2829
   PubMed Web of Science ®Google Scholar
• Gabrielsson B G, Carmignac D F, Flavell D M, Robinson I C. Steroid regulation of growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids in the rat. Endocrinology 1995; 136: 209–217
   PubMed Web of Science ®Google Scholar
• Brand P L. Inhaled corticosteroids reduce growth. Or do they?. Eur Respir J 2001; 17: 287–94
   PubMed Web of Science ®Google Scholar
• Leone F T, Fish J E, Szefler S J, West S L, for the Expert Panel on Corticosteroid Use. Systemic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma. Chest 2003; 124: 2329–2340
   PubMed Web of Science ®Google Scholar
• Ostrom N K. Women with asthma: a review of potential variables and preferred medical management. Ann Allergy Asthma Immunol 2006; 96: 655–665
   PubMedGoogle Scholar
• Chay O M, Goh A, Lim W H, Leong K H, Lou J. Effects of inhaled corticosteroid on bone turnover in children with bronchial asthma. Respirology 1999; 4: 63–67
   PubMedGoogle Scholar
• Allen H D, Thong I G, Clifton-Bligh P, Holmes S, Nery L, Wilson K B. Effects of high-dose corticosteroids on bone metabolism in prepubertal children with asthma. Pediatr Pulmonol 2000; 29: 188–193
   PubMedGoogle Scholar
• Walters J AE, Wood-Baker R, Walters E H. Long-acting β2-agonists in asthma: an overview of Cochrane systematic reviews. Respiratory Med 2005; 99: 384–395
   PubMed Web of Science ®Google Scholar
• Ram F S, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003; 58: 580–584
   PubMed Web of Science ®Google Scholar
• Jackson C M, Lipworth B. Benefit-risk assessment of long-acting β2-agonists in asthma. Drug Safety 2004; 27: 243–270
   PubMed Web of Science ®Google Scholar
• Lipworth J, Aziz I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. J Allergy Clin Immunol 1999; 103: 88–92
   PubMedGoogle Scholar
• Lotvall J. The long and short of β2-agonists. Pulm Pharmacol Ther 2002; 15: 497–501
   PubMed Web of Science ®Google Scholar
• Adams B K, Cydulka R K. Asthma evaluation and management. Emerg Med Clin North Am 2003; 21: 315–330
   PubMedGoogle Scholar
• Bristow M R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558–569
   PubMed Web of Science ®Google Scholar
• Sears M R. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002; 110: S322–S328
   PubMedGoogle Scholar
• Jouven X, Desnos M, Guerot C, Ducimetiere T. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999; 99: 1978–1983
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera M G, Donner C. Inhaled β2-adrenoceptor agonists. Cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65: 1596–1610
   Google Scholar
• Guhan A r, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield A E. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55: 650–656
   PubMed Web of Science ®Google Scholar
• Ostrom N K. Tolerability of short-term, high dose formoterol in healthy volunteers and patients with asthma. Clin Ther 2003; 25: 2635–2646
   PubMedGoogle Scholar
• Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till M D. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 1998; 54: 141–147
   PubMed Web of Science ®Google Scholar
• Lipworth B J. Revisiting interactions between hypoxaemia and β2-agonists in asthma. Thorax 2001; 56: 506–507
   PubMedGoogle Scholar
• Zimmer G, Dahinten A, Fitzner A, Halbig S, Noll T, Treusch F, Libertus H. β-agonists bronchodilators: comparison of dose/response in working rate heart. Chest 2000; 117: 519–529
   PubMedGoogle Scholar
• Bisgaard H. Long acting β2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmunol 2000; 29: 221–234
   PubMed Web of Science ®Google Scholar
• Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, Bailey M, Wilson J W, Walters Haydn E. An anti-inflammatory effect of salmeterol, a long-acting beta 2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493–1499
   PubMed Web of Science ®Google Scholar
• Kay L J, Peachell P T. Mast cell beta2-adrenoceptor. Chem Immunol Allergy 2005; 87: 145–153
   PubMedGoogle Scholar
• Roberts J A, Bradding P, Britten K M, Walls A F, Wilson S, Gratziou C, Holgate S T, Howarth P H. The long acting β2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14: 275–282
   PubMed Web of Science ®Google Scholar
• Currie G P, Lee D KC. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma. Chest 2005; 128: 2954–2962
   PubMed Web of Science ®Google Scholar
• Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 1998; 158: S146–S153
   PubMed Web of Science ®Google Scholar
• McGraw D W, Almoosa K F, Paul R J, Kobilka B K, Liggett S B. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholiase C underlies the airway beta-agonist paradox. J Clin Invest 2003; 112: 619–626
   PubMedGoogle Scholar
• Taylor D R, Sears M R, Cockcroft D W. The beta-agonist controversy. Med Clin North Am 1996; 156: 988–991
   Google Scholar
• Garcia R, Guerra P, Feo F. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. J Invest Allergol Clin Immunol 2001; 11: 176–182
   PubMed Web of Science ®Google Scholar
• D'Urzo A D, Chapman K R, Cartier A, Hargreave F E, Fitzgerald M, Tesarowski D. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest 2001; 119: 714–719
   PubMedGoogle Scholar
• Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer R J. Serious asthma exacerbations in asthmatics treated with high-doses of formoterol. Chest 2003; 112: 72–78
   Google Scholar
• Green S A, Turki J, Bejarano P, Hall I P, Liggett S B. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13: 25–33
   PubMed Web of Science ®Google Scholar
• Tan S, Hall I P, Dewar J, Dow E, Lipworth B. Association between genetic polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350: 995–999
   PubMed Web of Science ®Google Scholar
• Lee D KC, Currie G P, Hall I P, Lima J J, Lipworth B J. The arginine-16 β2-adrenoceptor polymorphism predispose to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2003; 57: 68–75
   Web of Science ®Google Scholar
• Martinez F D. Safety of long-acting beta-agonists. An urgent need to clear the air. N Engl J Med 2005; 353: 2637–2639
   PubMed Web of Science ®Google Scholar
• Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 1993; 306: 1034–1037
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Salmeterol (Serevent) asthma trial halted early. Can Med Assoc J 2003; 168: 738
   Google Scholar
• Boulet L P, Becker A, Berubè D, Beveridge R, Ernst P. On behalf of the Canadian Asthma Consensus Group. Summary of recommendations from the Canadian Asthma Consensus Report. Can Med Assoc J 1999; 161: S1–S12
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Szefler S. Long-acting β2-agonists and paediatric asthma. Lancet 2006; 367: 286–288
   PubMed Web of Science ®Google Scholar
• Bisgaard H. Effect of long-acting β2-agonists on exacerbation rates of asthma in children. Pediatr Pulmunol 2003; 36: 391–398
   PubMed Web of Science ®Google Scholar
• Anderson H R, Ayres J G, Sturdy P M, Bland J M, Butland B K, Peckitt C, Taylor J C, Victor C R. Bronchodilator treatment and deaths from asthma: case-control study. Br Med J 2005; 330: 117
   PubMed Web of Science ®Google Scholar
• Keam S J, Lyseng-Williamson K A, Goa K L. Pranlukast. A review of its use in the management of asthma. Drugs 2003; 63: 991–1019
   PubMed Web of Science ®Google Scholar
• Gawchik S M, Saccar C L. Role of antileukotriene agents in asthma therapy. J Am Osteopath Assoc 2000; 100: 37–42
   Google Scholar
• Barnes N C, de Jong B, Miyamoto T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 1997; 111: 52S–60S, suppl
   Google Scholar
• Hata D, Shiota M, Tamura Y, Miyazaki M, Ohmura K, Seto S, Furusho K. The effectiveness of the long-term treatment with pranlukast in pediatric patients with mild to moderate asthma. Arerugi 2002; 51: 400–410
   PubMedGoogle Scholar
• Mikawa H, Baba M. Efficacy and safety of a leukotriene antagonist; ONO-1078 dry syrup, on paediatric bronchial asthma-dose finding study in a multi-center, open trial. Rinsho Iyaku 1997a; 13: 395–421
   Google Scholar
• Mikawa H, Baba M, Nakashima M. Clinical uselfulness of a leukotriene antagonist; pranlukast dry syrup on pediatric bronchial asthma in multi-center comparative double-blind clinical study with oxatomide dry syrup. Rinsho Iyaku 1997b; 13: 423–456
   Google Scholar
• Grossman J, Fairferman I, Dubb J W, Tompson D J, Busse W, Bronsky E, Montanaro A, Southern L, Tinkelman D. Results of the first US double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997; 34: 321–328
   PubMed Web of Science ®Google Scholar
• Kohrogi H, Iwagoe H, Fujii K, Hamamoto J, Fukuda K, Hirata N, Kawano O, Matsumoto M, Suga M, Ando M. The role of cysteinyl leukotrienes in the pathogenesis of asthma: clinical study of leukotriene antagonist pranlukast for 1 year in moderate and severe asthma. Respirology 1999; 4: 319–323
   PubMedGoogle Scholar
• Obase Y, Shimoda T, Tomari S, Mitsuta K, Fukushima C, Kawano T, Matsuse H, Kohno S. Efficay and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year follow up study. Ann Allergy Asthma Immunol 2001; 87: 43–47
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Fujishima T, Tanaka H, Kon H, Saikai T, Suzuki A, Nakatsugawa M, Abe S. Churg-Strauss syndrome after reduction of inhaled corticosteroid in a patient treated with pranlukast for asthma. Intern Med 2001; 40: 432
   PubMedGoogle Scholar
• Kinoshita M, Shiraishi T, Koga T, Ayabe M, Rikimaru T, Oizumi K. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol 1999; 103: 534–535
   PubMed Web of Science ®Google Scholar
• Hayashi S, Furuya S, Imamura H. Fulminant eosynophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal. Heart 2001; 86: E7
   PubMedGoogle Scholar
• Schurman S J, Alderman J M, Massanari M, Lacson A G, Perlman S A. Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast. Chest 1998; 114: 1220
   PubMed Web of Science ®Google Scholar
• Takahashi N, Iwanaga T, Aizawa H, Koto H, Watanabe K, Kishikawa R, Ikeda T, Shoji S, Nishima S, Hara N. Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist. Intern Med 2001; 40: 791–794
   PubMedGoogle Scholar
• Spector S, Miller C J, Glass M. Management of asthma with zafirlukast. Clinical experience and tolerability profile. Drugs 1996; 52(suppl 6)36–46
   PubMedGoogle Scholar
• Townley R, Glass M, Minkwitz M C. Six-week, dose-escalation study with zafirlukast in patients with mild to moderate asthma. Eur Respir J 1995; 8: 288
   Google Scholar
• Pearlman D S, Ostrom N K, Bronski E A, Bonuccelli C M, Hanby L A. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 1999; 134: 256–259
   PubMedGoogle Scholar
• Adkins J F, Brogden R N. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. Drugs 1998; 55: 121–144
   PubMed Web of Science ®Google Scholar
• Pearlman D S, Lampl K L, Dowling P J, Miller C J, Bonuccelli C M. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther 2000; 22: 732–747
   PubMed Web of Science ®Google Scholar
• Bjermer L. Montelukast in the treatment of asthma as a systemic disease. Expert Rev Clin Immunol 2005; 1: 325–336
   PubMedGoogle Scholar
• Kemp J P, Dockhorn R J, Shapiro G G, Nguyen H H, Reiss T F, Seidenberg B C, Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424–428
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Zielen S, Garcia-Garcia M L, Johnston S L, Gilles L, Menten J, Tozzi C A, Polos P. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315–322
   PubMed Web of Science ®Google Scholar
• Altman L C, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, Reiss T F. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 1998; 102: 50–56
   PubMed Web of Science ®Google Scholar
• Van Adelsberg J, Moy J, Wei L X, Tozzi C A, Knorr B, Reiss T F. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-months-old patients with asthma. Curr Med Res Opin 2005; 21: 971–979
   PubMed Web of Science ®Google Scholar
• Price D. Tolerability of montelukast. Drugs 2000; 59: 35–42, suppl 1
   PubMedGoogle Scholar
• Garcia-Garcia M L, Wahn U, Gilles L, Swern A, Tozzi C A, Polos P. Montelukast compared with fluticasone for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116: 360–369
   PubMedGoogle Scholar
• Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei L X, Seidenberg B C, Reiss T F. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomised, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130: 487–495
   PubMed Web of Science ®Google Scholar
• Edelman J M, Preston S R, Turpin J A, et al. Parent and child preferences for montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in asthmatic children ages 6 to 11. Eur Resp J 1998; 12b: 18S, (suppl. 29)
   Google Scholar
• World Health Organization (WHO). Pharmaceutical Newsletter. WHO 1998; 9 & 10
   Google Scholar
• Barnes P J. Current and future therapies for airway mucus hypersecretion. Novartis Found Symp 2002; 248: 237–249
   PubMed Web of Science ®Google Scholar
• Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. J Asthma 2005; 42: 715–724
   PubMed Web of Science ®Google Scholar
• Greening A P, Ind P W, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids. Lancet 1994; 344: 219–224
   PubMed Web of Science ®Google Scholar
• Garcia-Marcos L, Shuster A, Barroso Cobos N. Inhaled corticosteroids plus long-acting beta2-agonists as a combined therapy in asthma. Expert Opin Pharmacother 2003; 4: 23–39
   PubMed Web of Science ®Google Scholar
• Greenstone I, Ni Chroinin C M, Masse V, Danish A, Magdalinos H, Zhang X, Ducharme F M. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; 4: CD005533
   Google Scholar
• Settipane R A. National Asthma Education and Prevention Program (NAEPP). Defining the effects of an inhaled corticosteroid and long-acting beta-agonist on therapeutic targets. Allergy Asthma Proc 2003; 24: 85–89
   PubMedGoogle Scholar
• Ni Chroinin M, Greenstone I R, Danish A, Magdolinos H, Masse V, Zhang X, Ducharme F M. Long-acting beta-2 agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma (Review). Cochrane Database Syst Rev 2005; 4: CD005535
   Google Scholar
• Sekhsaria S, Alam M, Sait T, Starr B, Parekh M. Efficacy and safety of inhaled corticosteroids with a long-acting beta2 agonist in asthmatic children under age 5. J Asthma 2004; 41: 575–582
   PubMed Web of Science ®Google Scholar
• Kirby S, Falcoz C, Daniel M J, Milleri S, Squassante L, Ziviani L, Ventresca G P. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781–791
   PubMedGoogle Scholar
• Heuck C, Heickendorff L, Wolthers O D. A randomized controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child 2000; 83: 334–339
   PubMed Web of Science ®Google Scholar
• Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P. The safety of twice-daily treatment with fluticasone proprionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005; 95: 66–71
   PubMed Web of Science ®Google Scholar
• Gupta R, Jindal D P, Kumar G. Corticosteroids: the mainstay in asthma therapy. Biorg Med Chem 2004; 12: 6331–6342
   PubMedGoogle Scholar
• Creticos P S. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists. Drugs 2003; 63: 1–20
   PubMedGoogle Scholar
• Leff A R. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med 2001; 52: 1–14
   PubMed Web of Science ®Google Scholar
• Sebaldt R J, Sheller J R, Oates J A, Roberts L J, FitzGerald G A. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A 1990; 87: 6974–6978
   PubMed Web of Science ®Google Scholar
• Ducharme F M. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br Med J 2002; 324: 1545–1548
   PubMed Web of Science ®Google Scholar
• Price D B, Hernandez D, Magyar P, Fiterman J, Beeh K M, James I G, Konstantopoulos S, Rojas R, van Noord J A, Pons M, Gilles L, Leff J A. Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 190–192
   PubMedGoogle Scholar
• Vaquerizo M J, Casan P, Castillo J, Perpiňa M, Sanchis J, Sobradillo V, Valencia A, Verea H, Viejo J L, Villasante C, Gonzalez-Esteban J, Picado C. CASIOPEA (Capacidad de Singulair Oral en la Prevencion de Exacerbaciones Asmaticas) Study Group. Effect of added montelukast to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 204–211
   PubMed Web of Science ®Google Scholar
• Wilson A M, Dempsey O J, Sims E J, Lipworth B J. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119: 1021–1026
   PubMed Web of Science ®Google Scholar
• Currie G P, Lee D K, Haggart K, Bates C E, Lipworth B J. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2002; 167: 1232–1238
   PubMedGoogle Scholar
• Storms W, Chervinsky P, Ghannam A F, et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 2004; 98: 1051–1062
   PubMed Web of Science ®Google Scholar
• Ram F S, Cates C J, Ducharme F M. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005; 1: CD003137
   PubMedGoogle Scholar
• Bremner P, Burgess C, Beasley R, Crane J, Purdie G, Pearce N, Beasley R. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6: 204–210
   PubMed Web of Science ®Google Scholar
• Fish J E, Israel E, Murray J J, Emmett A, Boone R, Yancey S W, Rickard K A. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423–430
   PubMed Web of Science ®Google Scholar
• Ilowite J, Webb R, Friedman B, Kerwin E, Bird S R, Hustad C M, Edelman J M. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004; 92: 641–648
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention, NIH Publication 02-3659; updated 2005.
   Google Scholar